PEGS Europe 2010 | Day 1  |  Day 2 

WEDNESDAY, 6 OCTOBER

13:00 Conference Registration

Improving Targeting with Antibody-Drug
Conjugates: Addressing Selectivity and Delivery

14:00 Chairperson’s Remarks

Stefan Barth, Ph.D., Head, Department of Pharmaceutical Product Development, Fraunhofer IME

14:05 Recombinant Human Multi-Domain Fusion Proteins

Stefan Barth, Ph.D., Head, Department of Pharmaceutical Product Development, Fraunhofer IME

Activated and dysregulated macrophages play a decisive role in the development of numerous inflammatory processes including progression of cancer. We have generated novel recombinant multi-domain immunotherapeutics by fusing different cytotoxic enzymes to a single chain fragment derived from the CD64-specific human antibody H22. Final aim is the application of tailor-made immunofusions not only considering the targeting moiety, but also the appropriate cytotoxic agent to specifically destroy diseased cells.

14:35 Antibodies-Conjugated Nanoparticles for Targeted Drug Delivery

Roland KontermannRoland Kontermann, Ph.D., Professor, Biomedical Engineering, Institute of Cell Biology & Immunology, University of Stuttgart

Nanoparticles such as liposomes and polymers are versatile carrier systems for delivery of therapeutic molecules, e.g. chemotherapeutic drugs, siRNA and proteins. Conjugation of antibodies, antibody fragments or antibody-mimetic scaffolds to the particle surface allow for active delivery to target cells, e.g. for tumor therapy. Binding to target cells has been shown to promote intracellular uptake and can improve selectivity and therapeutic efficacy. Examples for the generation and application of various targeted nanoparticulate drug carriers will be presented.

15:05 Toxicity-Reducing Potential of Extracorporeal Affinity Adsorption Treatment in Combination with Empowered Rune NilssonAntibodies in a Syngeneic Rat Tumor Model

Rune Nilsson, Ph.D., Associate Professor, Department of Oncology, Lund University

Extracorporeal affinity adsorption (ECAT) is a method that safely and efficiently reduces dose limiting toxicity associated with the administration of monoclonal antibodies conjugated with a cytotoxic payload. We have shown that in combination with ECAT higher doses of both radiolabeled (90Y and 177Lu) and drug-conjugated (auristatin) antibodies can be increased without increase of toxicity. During ECAT the circulating antibodies remaining in the blood is removed by in-line passage of the blood through an affinity adsorbent.

Sponsored by
Crucell
15:35 Refreshment Break





Selected Poster Presentations

16:00 A Recombinant Trispecifi c Single-Chain Fv Derivative Directed Against CD123 and CD33 Mediates Effective Elimination of Acute Myeloid Leukemia Cells by Dual Targeting

Georg H. Fey, Ph.D., Department of Biology, University of Erlangen-Nuremberg

16:15 Generation and In Vitro Characterization of Bispecifi c c-Met – HER1/HER2 Antibodies for the Treatment of Cancer

Raffaella Castoldi, Ph.D., Pharma Research and Early Development, Roche Diagnostics GmbH

16:30 End of Conference

18:30 – 21:00 BIOTECHNICA Night: Beer Hall, Full Dinner Reception, Live Band

(Please register to reserve your complimentary ticket ahead of time. No tickets will be available on-site.)